High levels of microRNA-214 are typically seen in UC patients, who have an increased risk of developing colon cancer. It is still unclear why colitis patients also develop colon cancer.
Thirty percent of all patients who complain of gastrointestinal pain are typically diagnosed with “indeterminate inflammatory bowel disease” by their gastroenterologist. Even if the patient has all available biomarkers and underwent a colonoscopy, many clinicians are still unable to determine if the patient has UC or Crohn’s disease.
In the two-year study, UCLA Jonsson Comprehensive Cancer Center member Dr. Dimitrios Iliopoulos and his colleague Dr. Christos Polytarchou, UCLA assistant professor of digestive diseases, examined 401 colon tissue samples from patients in the United States and Europe with UC, Crohn’s disease, irritable bowel syndrome, sporadic colorectal cancer, and colitis-associated colon cancer and compared them to specimens from people without these disorders or diseases.
The team hoped the research would assist physicians in diagnosing this disease correctly and provide the appropriate treatment, said Dr. Iliopoulos. They developed a systems approach that could expedite the drug discovery process by utilizing sophisticated computer programs and high-tech robotics that combines molecular and clinical information to identify the most important genes to create new drugs. The integration of this complex data is what led them to discover a new microRNA-214 chemical inhibitor to treat UC and colon cancer.
“The first steps of the drug discovery process usually take five to six years and by using our novel approach we expedited the drug discovery process only in two years,” said Iliopoulos, an associate professor of digestive diseases.
Previous studies have mentioned findings related to inflammatory responses in both sporadic and colitis-associated colon cancers, but it was unclear until now whether the inflammatory signals regulated the same signaling pathways.
“We evaluated this drug in mice with ulcerative colitis and colon tumors and found that in both cases it was highly effective to suppress these diseases,” said Iliopoulos.
Colorectal cancer, or colon cancer, is the third leading cause of cancer-related deaths in the United States (when men and women are considered separately), and the second leading cause when both sexes are combined. The American Cancer Society estimates 93,090 new cases of colon cancer and 39,610 new cases of rectal cancer will be diagnosed in the United States in 2015. Additionally, 49,700 people are expected to die from the disease this year.
Iliopoulos will continue testing the microRNA-214 inhibitor and will apply for an investigational new drug application with the Food and Drug Administration. He hopes to eventually begin phase I clinical trials for patients with UC next year.
The study is now available online, and the print edition will be released Oct. 1 in Gastroenterology.
This research was supported by the UCLA Clinical and Translational Science Institute, the Broad Medical Research Program, the Cancer Research Institute, and the Leona M. and Harry B. Helmsley Charitable Trust.
About UCLA’s Jonsson Comprehensive Cancer CenterUCLA's Jonsson Comprehensive Cancer Center has more than 500 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2015, the Jonsson Cancer Center was named among the top six cancer centers nationwide by U.S. News & World Report. For more information on the Jonsson Cancer Center, visit our website at http://www.cancer.ucla.edu.
RSS